CRTX
$45.61
Cortexyme
$1.53
3.47%
CRTX
Earnings Whisper ®
N/A
1st Quarter March 2020
Consensus:  $0.00
Revenue:  N/A
Tuesday
Jun 16
8:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CRTX reports earnings?
Beat
Meet
Miss

Where is CRTX's stock price going from here?
Up
Flat
Down
Stock chart of CRTX
Analysts
Summary of analysts' recommendations for CRTX
Score
Grade
Pivots
Resistance
$49.20
$47.95
$46.02

$44.77

Support
$42.84
$41.59
$39.66
Tweet
Growth
Description
CORNERSTONE THERAPEUTICS is a specialty pharmaceutical company focused on acquiring, developing and commercializing prescription products for the respiratory market. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. The Company also has a deep late-stage clinical pipeline with six regulatory approval submissions expected between 2009 and 2010. The Company's commercial strategy is to grow market share for its currently marketed products using its sales and marketing capabilities, acquire non-promoted or underperforming branded pharmaceutical products and implement life cycle management techniques to maximize the value of its currently marketed products, newly acquired products and product candidates that are in development.